ALUMIS INC. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 58/100
What the filing says
Alumis released Q2 2026 results showing 54% of patients achieved complete skin clearance (PASI 100) in the ONWARD3 psoriasis trial (n=773), supporting an NDA submission planned for Q4 2026. The company reported a $142.2M net loss for Q2 2026 (vs. $59.3M net income in Q2 2025), driven by a $41.8M impairment of the lonigutamab intangible asset following a decision to explore strategic alternatives. Cash position was $502.3M as of June 30, 2026, with runway into Q4 2027; Phase 2b SLE data anticipated Q3 2026.
Why this rating
Strong clinical efficacy supports regulatory path, but $41.8M impairment (23% of market cap) signals portfolio setback. Runway adequate but tightening. Clinical progress offset by asset write-down.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.